-
-
-
-
-
-
-
FDA accepts resubmitted drug application for rare pediatric disease
-
-
-
-
-
-
-
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
-
-
-
-
-
-
-
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
-
-
-
-
-
-
-
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
-
-
-
-
-
-
-
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

